Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review

Abstract Tyrosine kinase inhibitors (TKIs) are the key agents for treating CML and BCR–ABL+ B‐ALL. Dasatinib is a potent second‐generation TKI. Here, we have discussed the case of a 51‐year‐old gentleman diagnosed with B‐myeloid mixed‐phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR–ABL1p210,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Theresa Paul, Anil Yousaf Ellahie, Yazan Salah Almohtasib, Urshita Sinha, Halima El Omri
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2021-08-01
coleção:	eJHaem
Assuntos:	chylothorax Dasatinib glucose–lipid metabolism imatinib leukemia pleural effusion
Acesso em linha:	https://doi.org/10.1002/jha2.226
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!